Thanks hyder. Reposted with editing advice from Lasers...
This is my first post, but I've been lurking on your board for years.
I have accumulated shares in the 7 digit range, and I have only sold shares one time to pay some taxes. I have since repurchased those shares in triplicate, and I have no plans to sell any more shares until the buyout occurs.
Lasers, I want to wholeheartedly thank you for everything you contribute here. There have been weeks at a time when I only had time enough to log on and scan the board for what you posted. When it comes to ELTP, I am a strong subscriber to your philosophy of Buy, Hold, Accumulate.
On this subject, I think it has become apparent that ELI-200 is Oxy-IR (immediate-release oxycodone). ELI-201 is Oxy-ER (Oxycontin). ELI-202 is Percocet (acetominophen/oxycodone). And ELI-216 is once-daily Oxy-ER. I think the morphine formulation is probably ELI-300 and ELI-301, which are the only opioids listed on the website under Generic Pipeline (as in, generic Embeda). All other opioids are listed under Branded Pipeline.
I've gone back and re-read all the PR and CC's. NH never refers to ELI-200 as extended release. Nowhere on the website does it refer to ELI-200 as extended release. When asked about ELI-200 specifically on the CC, he cunningly referred to ELI-201 instead of answering the question as asked. I don't think this was by accident.
Obviously, ELI-201 is twice daily oxy. But that does not exclude ELI-200 also being an oxy formulation. The Withdrawal study specifically sets the dosing at every 6 hours-- this is OxyIR!
As far as I'm concerned, this is a major development. I am an internist with 10 years experience. I can count on one hand the number of times in my career that I've prescribed MS-Contin (twice daily morphine without ADT), and I've never once written for Embeda. Even OxyContin I've only written a half dozen times in 10 years. But I prescribe OxyIR a half dozen times per week. OxyIR is a standard order on my hospital admission order set. When a patient needs opioids, I write for OxyIR.
This is, in my opinion, a thrilling development. Many, many more scripts get written for immediate-release opioids than extended release. And how is Purdue going to challenge ADT Oxy-IR when they do not even manufacture it? Let them challenge ELI-201, and ELTP will be well-funded to fight them with ADT Oxy-IR (ELI-200).
Once again, Nasrat Hakim looks like the smartest guy at the party, and I cannot wait to see what he has in store for us in the future.
